Hatch-Waxman 2022 Year in Review

This event has ended.


Nearly 40 years ago, Congress signed into law the Hatch-Waxman Act, balancing the need for lower cost prescription drugs and the protection of pharmaceutical innovations. For both branded and generic drug developers, the Hatch-Waxman legal landscape continues to evolve through decisions by courts, U.S. Food and Drug Administration, and U.S. Patent and Trademark Office.

On January 4, 2023, please join principals Geoff Biegler and Megan Chacon for an overview of the Hatch-Waxman landscape in 2022. Our hosts will discuss:

  • Hatch-Waxman litigation trends
  • Select court cases and appellate guidance
  • The outlook for 2023

If you have any questions, please contact [email protected].